Your browser doesn't support javascript.
loading
Cost-minimization Analysis of Ginkgolide Injection versus Butylphthalide Injection in the Treatment of Ische- mic Stroke of Large-artery Atherosclerosis / 中国药房
China Pharmacy ; (12): 2235-2239, 2020.
Article in Chinese | WPRIM | ID: wpr-825654
ABSTRACT
OBJECTIVE:To eval uate therapeutic effic acy,safety and economical efficiency of Ginkgolide injection versus Butylphthalide injection in the treatment of ischemic stroke. METHODS :Among the GISAA of Ginkgolide injection in the treatment of ischemic stroke of large-artery atherosclerosis ,106 patients who were given Ginkgolide injection+Asprin enteric-coated tablets but did not use butylphthalide in any dosage in previous trial group were selected as ginkgolide group ;56 patients who were given Butylphthalide injection+Ginkgolide injection+Asprin enteric-coated tablets in previous placebo group were selected as control group. The effects ,safety and economical efficiency were compared between 2 groups. Effect indexes included recurrence rate , mortality,NIHSS score ,modified Rankin score (mRS),Barthel index and comprehensive efficacy. The safety indexes included incidence of bleeding event and adverse event during treatment. Cost-minimization analysis was used for economic evaluation. RESULTS:There was no statistical difference in recurrence rate ,mortality,NIHSS score ,the proportion of subjects with mRS 0-2,Barthel index ,comprehensive efficacy and the incidence of adverse event between 2 groups on 28th day after treatment (P> 0.05). NIHSS score of ginkgolide group was better than that of control group on 7th and 14th day (P<0.05). Results of cost-minimization analysis showed that total cost of ginkgdide group was (13 768.19±4 981.54)yuan on 14th day of treatment , which was significantly lower than (22 578.52±7 523.23)yuan of control group (P<0.01). The results of sensivity analysis indicated that the minimum lost analysis was stable. CONCLUSIONS :For the treatment of ischemic strokeginkgolide+aspirin is similar to butylphthalide+aspirin in improving clinical outcome and safety of 28 days,but is better than it in short-term efficacy of improving neurological deficit , and better short-term economical efficiency.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Controlled clinical trial / Health economic evaluation Language: Chinese Journal: China Pharmacy Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Controlled clinical trial / Health economic evaluation Language: Chinese Journal: China Pharmacy Year: 2020 Type: Article